🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions

    Laboratorios Tillomed Spain S.L.U

    Alzheimer's disease

    phase 1 other active

    1 trial
  2. Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg tablets versus edoxaban 60 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial
  3. Randomised, crossover bioequivalence clinical trial of escitalopram 10 mg capsules versus escitalopram 10 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Antidepressants

    phase 1 other active

    1 trial
  4. Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    diabetes

    phase 1 other active

    1 trial
  5. Randomised, crossover bioequivalence clinical trial of memantine 20 mg capsules versus memantine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Alzheimer’s disease

    phase 1 other active

    1 trial
  6. Randomised, crossover bioequivalence clinical trial of vortioxetine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Antidepressant

    phase 1 other active

    1 trial
  7. Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a single oral dose administration to healthy volunteers under fasting conditions in a crossover design.

    Lacuna Pharma Pty Ltd

    healthy volunteer

    phase 1 other active

    1 trial
  8. Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 1 other active

    1 trial
  9. Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

    Lacuna Pharma Pty Ltd

    Comparative bioavailability study under fasting conditions

    phase 1 other active

    1 trial
  10. Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is bioavailability)

    phase 1 other active

    1 trial
  11. Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial
  12. Randomized, open-label, single-dose, two-period, cross-over, bioequivalence study comparing Linagliptin 5 mg film-coated tablets (Vipharm S.A.) to Trajenta® 5 mg film-coated tablets (Boehringer Ingelheim) in healthy volunteers under fasting conditions.

    Alphapharm Pty Ltd

    Bioequivalence study in healthy volunteers under fasting conditions

    phase 1 other active

    1 trial
  13. Regorafenib in combination with temozolomide with or without radiotherapy in patients with newly diagnosed MGMT-Methylated, IDH wild-type glioblastoma. A phase I dose-finding study (REGOMA-2).

    Istituto Gentili S.r.l.

    MGMT-Methylated, IDH wild-type glioblastoma

    phase 1 other active

    1 trial
  14. Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.

    Recordati Ireland

    Post-bariatric hypoglycaemia

    phase 1 other active

    1 trial
  15. Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 1 other active

    1 trial
  16. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial
  17. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial
  18. Single Ascending Dose of SAB-176

    SAB Biotherapeutics

    PHA1A

    phase 1 small molecule active

    1 trial
  19. Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen

    Pfizer Australia Pty Ltd

    long-term female contraception

    phase 1 other active

    1 trial
  20. Single and multiple ascending dose of ZP9830 in healthy participants

    Zealand Pharma A/S

    Autoimmune diseases

    phase 1 other active

    1 trial
  21. Single dose intravenous injection of BBM 002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hemophilia A

    phase 1 gene therapy active

    1 trial
  22. Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial
  23. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    Bioavailability study in healthy volunteers under fed conditions.

    phase 1 other active

    1 trial
  24. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources